Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer ConsortiumPetros Grivas, Shuchi Gulati, Maheen Z. Abidi et al.|Annals of Oncology|2021Cited by 326
Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapyJennifer L. Crombie, Michael Dickinson, Tara Graff et al.|Blood|2024Cited by 132
NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017William G. Wierda, Hema Sundar, Andrew D. Zelenetz et al.|Journal of the National Comprehensive Cancer Network|2017Cited by 62
Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective studyDavid Qualls, Gilles Salles, Nicholas Lambert et al.|Blood|2023Cited by 47
Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignanciesMatthew S. Davids, Ian W. Flinn, Wojciech Jurczak et al.|Blood Advances|2021Cited by 21